| Literature DB >> 14716014 |
Robert F Klein1, John Allard, Zafrira Avnur, Tania Nikolcheva, David Rotstein, Amy S Carlos, Marie Shea, Ruth V Waters, John K Belknap, Gary Peltz, Eric S Orwoll.
Abstract
The development of osteoporosis involves the interaction of multiple environmental and genetic factors. Through combined genetic and genomic approaches, we identified the lipoxygenase gene Alox15 as a negative regulator of peak bone mineral density in mice. Crossbreeding experiments with Alox15 knockout mice confirmed that 12/15-lipoxygenase plays a role in skeletal development. Pharmacologic inhibitors of this enzyme improved bone density and strength in two rodent models of osteoporosis. These results suggest that drugs targeting the 12/15-lipoxygenase pathway merit investigation as a therapy for osteoporosis.Entities:
Mesh:
Substances:
Year: 2004 PMID: 14716014 DOI: 10.1126/science.1090985
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728